Establishment Labs Holdings Inc. (NASDAQ:ESTA) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ET

Company Participants

Raj Denhoy - Chief Financial Officer

Juan José Chacón Quirós - Chief Executive Officer

Conference Call Participants

Allen Gong - JPMorgan Chase & Co.

Joanne Wuensch - Citigroup Inc.

Joshua Jennings - TD Cowen

George Sellers - Stephens Inc.

Sam Eiber - BTIG

Anthony Petrone - Mizuho Financial Group, Inc.

Operator

Good afternoon. Welcome to Establishment Labs’ Fourth Quarter 2023 Earnings Call. At this time, all participants will be in a listen-only mode. At the end of this call, we will open the line for a question-and-answer session. Instructions will follow at that time. As a reminder, today’s call is being recorded.

I will now turn the call over to Raj Denhoy, Chief Financial Officer. Please go ahead.

Raj Denhoy

Thank you, operator, and thank you everyone for joining us. With me today is Juan José Chacón Quirós, our Chief Executive Officer. Following our prepared remarks, we’ll take your questions.

Before we begin, I would like to remind you that comments made by management during this call will include forward-looking statements within the meaning of federal securities laws. These include statements on Establishment Labs’ financial outlook and the company’s plans and timing for product development and sales. These forward looking statements are based on management’s current expectations and involve risks and uncertainties. For discussion of the principal risk factors and uncertainties that may affect our performance or cause actual results to differ materially from these statements, I encourage you to review our most recent annual and quarterly reports on Form 10-K and Form10-Q, as well as other SEC filings which are available on our website at establishmentlabs.com.

I’d also like to remind you that our comments may include certain non-GAAP financial measures with respect to our performance, including but not limited to sales results which can be stated on a constant currency basis or the company’s earnings, which can be stated as adjusted EBITDA. Reconciliations to comparable GAAP financial measures for non-GAAP measures, if available, may be found in today’s press release which is available on our website.

Please also note that Establishment Labs receive an investigational device exemption from the FDA for Motiva Implants and is undergoing a clinical trial to support regulatory approval in the United States. We continually seek to expand the geographies in which our products are regulatory approved. Please check with your local authority for specific product availability. The content of this conference call contains time-sensitive information accurate only as of the date of this live broadcast, February 28, 2024.